GlassScriptPhysician profile
Alfred A Chu
NPI 1922181916
$5,538.46
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,899 · 2020: $607 · 2021: $1,705 · 2022: $306 · 2023: $20.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $2,658.12 | 2019-2021 | |
| Abbott Laboratories | $1,364.97 | 2019-2023 | Jeti |
| Cordis US Corp. | $1,016.62 | 2021 | |
| Amarin Pharma, INC. | $201.95 | 2019 | |
| Medtronic Vascular, INC. | $102.83 | 2019 | |
| Boston Scientific Corporation | $81.87 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.32 | 2021 | |
| Cardinal Health 200 LLC | $19.73 | 2019 | |
| Amgen INC. | $18.75 | 2021 | |
| Medtronic, INC. | $16.03 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.94 | 2022 | |
| Esperion Therapeutics, INC. | $11.21 | 2021 | |
| Cardiovascular Systems INC. | $10.12 | 2021 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfred Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.